Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Thorac Cancer. 2023 Mar;14(8):779-782. doi: 10.1111/1759-7714.14818. Epub 2023 Feb 6.
Small cell lung cancer (SCLC) is an aggressive malignancy associated with poor prognosis. Metastasis to sites outside the chest at the time of initial diagnosis, such as bone, brain, and liver metastasis have been found in most SCLC patients. Iris metastases from SCLC have rarely been previously reported, and often cause eye pain and blindness in patients. Here, we report a patient with SCLC who presented with iris metastasis in the right eye and metastasis in the left adrenal gland due to disease progression on first-line therapy, which subsequently caused pain and blindness in the right eye. The patient was treated with second-line irinotecan combined with anlotinib and atezolizumab and did not receive any local treatment in the right eye. After only one cycle of treatment, the iris metastases in the right eye were smaller than before, and the visual acuity in the right eye recovered. At the same time, her left adrenal metastases were also significantly smaller than before. Our case suggests that systemic therapy with effective treatment options can similarly improve iris metastases in patients.
小细胞肺癌（SCLC）是一种侵袭性恶性肿瘤，预后不良。在初始诊断时，大多数 SCLC 患者已经发生了胸部以外部位的转移，如骨、脑和肝转移。SCLC 的虹膜转移以前很少有报道，并且经常导致患者眼痛和失明。在这里，我们报告了一名 SCLC 患者，由于一线治疗后疾病进展，该患者右眼出现虹膜转移，同时左侧肾上腺转移，继而导致右眼疼痛和失明。该患者接受了二线伊立替康联合安罗替尼和阿替利珠单抗治疗，并且右眼未接受任何局部治疗。仅进行了一个周期的治疗后，右眼的虹膜转移灶比以前小，右眼的视力恢复。同时，她左侧肾上腺的转移灶也明显小于以前。我们的病例表明，具有有效治疗选择的全身治疗同样可以改善患者的虹膜转移。
